FDA
-
-
-
-
-
-
-
Zymeworks reports phase 1 data for cancer drug ZW191
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)
-
-
-
-
-
-
-
Zymeworks names Kristin Stafford as CFO effective April 1
-
-
-
-
-
-
-
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
-
-
-
-
-
-
-
Zymeworks Outlines Strategic Priorities and Outlook for 2026
-
-
-
-
-
-
-
Zymeworks reports positive phase 3 trial results for cancer drug Ziihera
-
-
-
-
-
-
-
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
-
330,175 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

